BioSpace News Archive

MorphoSys AG and Incyte announced the first patient has been dosed in the placebo-controlled Phase 3 inMIND study evaluating the efficacy and safety of tafasitamab or placebo in combination with lenalidomide and rituximab in patients with relapsed or refractory follicular lymphoma or marginal zone lymphoma.

Conformis, Inc. (NASDAQ:CFMS) announced today that it has entered into a license agreement with Paragon 28, Inc., granting Paragon 28 a non-exclusive license under a subset of Conformis’ U.S. patents for the use of patient-specific instruments with off-the-shelf implants in Paragon 28’s APEX 3D™ Total Ankle Replacement System.

DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced the company has become a member of The Skin Cancer Foundation Corporate Council.

Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for first quarter ended March 31, 2021 before the market opens on May 6, 2021, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.

180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, announced today that it received an expected letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC

The federal budget highlighted the vital role biotechnology innovation is playing in addressing the COVID-19 pandemic while aiming to prepare for future pandemic needs and serves as one of the identified key sectors set to drive the economic recovery for Canada.

Prenetics Limited, a global leader in diagnostics and genetic testing, Oxford University and Oxford Suzhou Centre for Advanced Research (OSCAR) have signed multi-million dollar collaboration agreements to further develop the award-winning OxLAMP™ technology, a rapid, molecular testing technology for infectious diseases.

Increasing scope of applications and frequent research activities drive adoption of new urology devices in emerging markets with relatively lower regulatory barriers.

The global market for sternal closure systems has witnessed rapid traction in the past few years owing to the vast rise in target population and a steady rise in the number of surgeries undertaken for treating complex cardiovascular conditions.

Pen injectors are self-injection medical devices designed for multiple injections of medicines and hormones for patients requiring frequent dosage for long term management of medical conditions such as diabetes.